AZD-9291 mesylate

Research use only, not for human use.

A potent, selective, third-generation irreversible inhibitor of mutant EGFR with IC50s of 1/12/5 nM for L858R-T790M/L858R/L861Q respectively.

A potent, selective, third-generation irreversible inhibitor of mutant EGFR with IC50s of 1/12/5 nM for L858R-T790M/L858R/L861Q respectively; weak activity against wt EGFR (IC50=184 nM); inhibits signaling pathways and cellular growth in both EGFRm(+) and EGFRm(+)/T790M(+) mutant cell lines in vitro; exhibits tumor regression in EGFR-mutant tumor xenograft and transgenic models; orally active.Lung Cancer Approved

Osimertinib mesylate;Mereletinib mesylate;AZD9291 mesylate;AZD 9291 mesylate

Angiogenesis

EGFR

EGFR(L858R);EGFR(L858R/T790M);EGFRL858R/T790M;EGFRL858R

Cancer

Lung Cancer

1421373-66-1

595.71

C29H37N7O5S

>98% (HPLC)

DMSO

CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O

2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1)

(-20℃)

With Ice Pack

≥ 2 years